|
Video: What is a Stock Split?
|
|
Hoth Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs. Co. is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). In addition, Co. is evaluating a peptide that may be used to slow the transmission of SARS-CoV-2 (HT-002). Co. is also developing a diagnostic device via a mobile device. Co. has interests in assets being developed by third parties including a treatment for patients with lupus. According to our HOTH split history records, Hoth Therapeutics has had 1 split. | |
|
Hoth Therapeutics (HOTH) has 1 split in our HOTH split history database. The split for HOTH took place on October 26, 2022. This was a 1 for 25 reverse split, meaning for each 25 shares of HOTH owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split.
When a company such as Hoth Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the HOTH split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Hoth Therapeutics shares, starting with a $10,000 purchase of HOTH, presented on a split-history-adjusted basis factoring in the complete HOTH split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
02/19/2019 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$176.50 |
|
End price/share: |
$1.16 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.34% |
|
Average Annual Total Return: |
-62.07% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$65.71 |
|
Years: |
5.18 |
|
|
|
Date |
Ratio |
10/26/2022 | 1 for 25 |
|
|